Drugs that contain Tedizolid Phosphate

1. Drug name - SIVEXTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(5 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(5 years from now)

US10442829 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

US9624250 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

US8426389 CUBIST PHARMS LLC Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Dec, 2030

(8 years from now)

CN102439006A CUBIST PHARMS LLC Crystalline Form Of R)-3-(4-(2-(2-Methyltetrazol-5-Yl)Pyridin-5-Yl)-3-Fluorophenyl)-5-Hydroxymethyl Oxazolidin-2-One Dihydrogen Phosphate
Jun, 2017

(5 years ago)

CN102702184A CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2021

(9 months ago)

CN102516238A CUBIST PHARMS LLC Novel Derivatives Of Oxazolidinone
Dec, 2021

(9 months ago)

CN1894242A CUBIST PHARMS LLC New Oxazolidone Derivative
Dec, 2021

(9 months ago)

CN102702184B CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2021

(9 months ago)

CN1894242B CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2021

(9 months ago)

CN102516238B CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2021

(9 months ago)

CN101982468B CUBIST PHARMS LLC Oxazolidinone Derivatives And Pharmaceutical Composition Containing The Derivative
Jan, 2022

(9 months ago)

CN101982468A CUBIST PHARMS LLC An Oxazolidinone Derivative And Pharmaceutical Composition Comprising The Same
Jan, 2022

(9 months ago)

IN200602167P4 CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2024

(2 years from now)

IN236862B CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2024

(2 years from now)

EP2305657B1 CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2024

(2 years from now)

EP2305657A3 CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2024

(2 years from now)

EP2305657A2 CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2024

(2 years from now)

EP1699784B1 CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2029

(7 years from now)

EP1699784A4 CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2029

(7 years from now)

EP1699784A1 CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2029

(7 years from now)

EP2393808B1 CUBIST PHARMS LLC Crystalline Form Of R)-3-(4-(2-(2-Methyltetrazol-5-Yl)Pyridin-5-Yl)-3-Fluorophenyl)-5-Hydroxymethyl Oxazolidin-2-One Dihydrogen Phosphate
Feb, 2030

(7 years from now)

EP2393808A1 CUBIST PHARMS LLC Crystalline Form Of R)-3-(4-(2-(2-Methyltetrazol-5-Yl)Pyridin-5-Yl)-3-Fluorophenyl)-5-Hydroxymethyl Oxazolidin-2-One Dihydrogen Phosphate
Feb, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9988406 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate Feb, 2030

(7 years from now)

US10065947 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate Feb, 2030

(7 years from now)

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.